Boyi Yu

Boyi Yu

Auto-generated profile, based on publicly available information

Boyi Yu

Advanced Data Science Division, Research Center of Advanced Science and Technology, The University of Tokyo , 4-6-1 Komaba, Meguro-ku 153-8904, Tokyo

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2024 in Molecular and Cellular Probes
Verified
Journal Article
Open access
LLLinjing Li
Linjing Li
YGYuting Gao
Yuting Gao
BYBoyi Yu
Boyi Yu
JZJiahao Zhang
Jiahao Zhang
GMGuorong Ma
Guorong Ma
XJXiaodong Jin
Xiaodong Jin
As one of the earliest discovered lncRNA molecules, lncRNA H19 is usually expressed in large quantities during embryonic development and is involved in cell differentiation and tissue formation. In recent years, the role of lncRNA H19 in tumors has been gradually recognized. Increasing evidence suggests that its aberrant expression is closely related to cancer development. LncRNA H19 as an oncogene not only promotes the growth, proliferation, invasion and metastasis of many tumors, but also develops resistance to treatment, affecting patients' prognosis and survival. Therefore, in this review, we summarise the extensive research on the involvement of lncRNA H19 in tumor progression and discuss how lncRNA H19, as a key target gene, affects tumor sensitivity to radiotherapy, chemotherapy and immunotherapy by participating in multiple cellular processes and regulating multiple signaling pathways, which provides a promising prospect for further research into the treatment of cancer.

23 September 2024 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
BYBoyi Yu
Boyi Yu
GNGenta Nagae
Genta Nagae
YMYutaka Midorikawa
Yutaka Midorikawa
KTKenji Tatsuno
Kenji Tatsuno
BDBhaskar Dasgupta
Bhaskar Dasgupta
HUHiroki Ueda
Hiroki Ueda
N6-methyladenosine (m6A) is one of the most abundant and well-known modifications in messenger RNAs since its discovery in the 1970s. Recent studies have demonstrated that m6A is involved in various biological processes, such as alternative splicing and RNA degradation, playing an important role in a variety of diseases. To better understand the role of m6A, transcriptome-wide m6A profiling data are indispensable. In recent years, the Oxford Nanopore Technology Direct RNA Sequencing (DRS) platform has shown promise for RNA modification detection based on current disruptions measured in transcripts. However, decoding current intensity data into modification profiles remains a challenging task. Here, we introduce the m6A Transcriptome-wide Mapper (m6ATM), a novel Python-based computational pipeline that applies deep neural networks to predict m6A sites at a single-base resolution using DRS data. The m6ATM model architecture incorporates a WaveNet encoder and a dual-stream multiple-instance learning model to extract features from specific target sites and characterize the m6A epitranscriptome. For validation, m6ATM achieved an accuracy of 80% to 98% across in vitro transcription datasets containing varying m6A modification ratios and outperformed other tools in benchmarking with human cell line data. Moreover, we demonstrated the versatility of m6ATM in providing reliable stoichiometric information and used it to pinpoint PEG10 as a potential m6A target transcript in liver cancer cells. In conclusion, m6ATM is a high-performance m6A detection tool, and our results pave the way for future advancements in epitranscriptomic research.